AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05045989 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Residence-based testing participation pilot (SARS-CoV-2 testing with relaxed social distancing restrictions)
Description: SARS-CoV-2 asymptomatic saliva testing (as available to all students at staff at the participating university) delivered with relaxed social distancing (behavioural element) in two halls of residence.
Study NCT06457672 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Group I
Description: Complete Crown technique of superimposition
Study NCT06457672 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Group II
Description: Gold standard technique of superimposition
Study NCT04717830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamezumab
Description: solution for infusion
Study NCT06272331 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Low-protein plant-based drink
Description: Ingestion of a low-protein plant-based drink
Study NCT06272331 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High-protein plant-based drink
Description: Ingestion of a high-protein plant-based drink
Study NCT06272331 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cow's milk
Description: Ingestion of cow's milk
Study NCT04285320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravesical antibiotic instillation
Description: Based on the participant's allergy and antibiotic resistance profile, one of the following three antibiotics will be instilled intravesically via a latex free BARD® 12 French Foley catheter for a total of 6-8 instillations (2 instillations/week) according to the Atlantic Health System Urogynecology Division antibiotic bladder instillation standard protocol:~* Amikacin-30 mg in 60 ml of sterile water~* Gentamycin-80mg in 60ml sterile water~* Tobramycin-80 mg in 100 ml of sterile water
Study NCT04285320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic oral suppressive therapy
Description: In the antibiotic oral suppression therapy arm, one of the following routinely used antibiotics will be prescribed for a total of 3 months according to the American Urogynecology Society Guidelines and based on the participant's allergy and antibiotic resistance profile:~* Trimethoprim daily (100 mg)~* Trimethoprim/sulfamethoxazole daily (40 mg/200 mg)~* Trimethoprim/sulfamethoxazole every 3 days (40 mg/200 mg)~* Nitrofurantoin monohydrate/macrocrystals daily (50 mg)~* Nitrofurantoin monohydrate/macrocrystals daily (100 mg)~* Cephalexin daily (125 mg)~* Cephalexin daily (250 mg)~* Fosfomycin every 10 days (3 grams)
Study NCT06144762 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological/Vaccine: Blood sample and tissue sample
Description: During the surgery :~Tissus sample : primary tumor and metastasis blood sample : 3 EDTA tubes ex vivo MRI data
Study NCT06433856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Water Immersion
Description: Cold water immersion consists in 12 min standing in 10 °C water
Study NCT06433856 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percussive Massage Therapy
Description: Percussive massage therapy is performed with a massage gun on the thigh muscles for 12 min
Study NCT05698875 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High glycaemic load breakfast meal
Description: Breakfast meal
Study NCT05698875 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High glycaemic load breakfast meal with additional 10g protein
Description: Breakfast meal
Study NCT05698875 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Medium glycaemic load breakfast meal
Description: Breakfast meal
Study NCT04851093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCM granule plus conventional drug
Description: All patients will receive conventional drug according to 2020 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Medicine Diagnosis Treatment Guidelines.~Yiqiwenfei granule for qi deficiency and internal cold fluid syndrome.~Fuzhengqinghua granule for qi and yin deficiency and unclean phlegm heat syndrome.~Fuzhengzaohua granule for lung and spleen qi deficiency and phlegm-damp amassing in lung syndrome.~TCM granule (Jiangyin Tian Jiang Pharmaceutical Co.,Ltd, 10g/packet) will be administered twice daily for 8 weeks.
Study NCT04851093 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TCM placebo granule plus conventional drug
Description: All patients will receive conventional drug according to 2020 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Medicine Diagnosis Treatment Guidelines.~Placebo Yiqiwenfei granule for qi deficiency and internal cold fluid syndrome.~Placebo Fuzhengqinghua granule for qi and yin deficiency and unclean phlegm heat syndrome.~Placebo Fuzhengzaohua granule for lung and spleen qi deficiency and phlegm-damp amassing in lung syndrome.~TCM placebo granule (Jiangyin Tian Jiang Pharmaceutical Co.,Ltd, 10g/packet) will be administered twice daily for 8 weeks.~The appearance, weight, color and odor of the preparation are the same as those of experimental group.~The placebo granule consists of dextrin, bitter and 5% of the TCM granule.
Study NCT05849961 — intervention group
Intervention type: DEVICE
Intervention: Exactech Hip Systems
Description: The Exactech Hip System comprises a fixed-bearing hip joint prostheses used in treating human hip joint diseases as part of THA. These prostheses include a combination of the components and are available in a range of sizes to accommodate varying anatomical requirements.
Study NCT05947240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercises
Description: The treatment group patients will perform upper extremity aerobic exercises by using an arm ergometer under the supervision of a physiotherapist.
Study NCT05947240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: active alternating movements for the upper limbs
Description: The control group patients will perform functional active alternating movements for the upper limbs at home involving three sets with 10 repetitions and a rest interval between 1- and 2-minute. Intervention will be for 3 times a week or 6 weeks.
Study NCT04133077 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood samples collection
Description: Serology and genetic analyses will be performed in patients blood samples
Study NCT04480151 — intervention group
Intervention type: OTHER
Intervention: standard of care
Description: retrospective study: standard of care
Study NCT06217614 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: (Manuka honey-green tea)
Description: Manuka honey is a natural honey, and green tea are herbs Dried green tea leaves (100 gm) will be soaked into 500 ml of methanol solution for two days. Green tea plus ginger mouthwash was prepared by adding 50% green tea extract and 50% ginger extract. After extraction, the extract was filtered and taker to the vacuum evaporator to remove the solvent.~The mouthwash was prepared by adding 3 gm of each extract, 0.12 gm sodium saccharin, and one liter distilled water, then every 20 ml of Manuka honey were added in 100 ml of (green tea and ginger solution). Finally, the mixture was stirred vigorously until all the particles were dissolved. Thereafter the obtained mixture was filtered. The mouthwash then filled in sterilized amber color bottles of 250 ml each.~According to similar studies performed in this field, the patients used a 20ml of (Manuka honey-green tea- ginger) mouthwash three times a day (preferably after their meals), kept it for one minute, and then poured it out
Study NCT04695613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminoacid
Description: amino acid infusion 150 ml/kg/hr starting preoperative
Study NCT04695613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: magnesium sulphate bolus and infusion 60 mg/kg starting preoperative
Study NCT05721807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: functional magnetic stimulation
Description: When applying functional magnetic stimulation, the stress urinary incontinence program P2 stress was chosen. The first 20 min. current frequency was 35 Hz, modulation - rising amplitude (from 0 to maximum per second), total wave duration 12 s. active time 6 s., pause time 6 s. After 20 min. current frequency changed to 5 Hz, modulation and wave remained the same. After 2 min. current frequency changed to 35 Hz, modulation - amplitude, one-sided sinusoidal, wave remained the same. The total duration of the procedure was 30 min. A magnetic spring is installed at the bottom of the chair. During the treatment, each subject was instructed to sit on a chair so that the perineum was centered on the spring and that the subjects felt the contraction of the muscles. The intensity of the magnetic field was adjusted so as to feel comfortable during the study procedure (Vadalà et al., 2017).
Study NCT05721807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pelvic floor muscle training program
Description: The program consisted of two parts. From procedures 1 to 6, 6 exercises were performed, after 6 times the exercises were adjusted, and from procedures 7 to 12, another 5 exercises were performed. The program consists of breathing, pelvic floor muscle strength, endurance, speed training exercises and exercises to strengthen the thighs, buttocks, deep back and deep abdominal muscles. Exercises were performed in 2 sets of 10 repetitions at an intensity from various positions: lying on the back, side, sitting, quadruped (Oliveira et al., 2017; Walton et al., 2019).
Study NCT05667415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: disulfiram and cisplatin
Description: on the first day of treatment, patients were given intravenous drip of 80mg/m2 cisplatin, and 21 days was a course of treatment, lasting for 6 courses. Take 400mg disulfiram orally every day, and continue to use it until the end of chemotherapy. According to the patient's tolerance to disulfiram, the dose of disulfiram can be re-evaluated during the treatment, and the lowest dose is 125mg per day. The clinical symptoms, signs and adverse reactions of patients were observed, and the treatment effect of patients was evaluated after two consecutive cycles with 3 weeks as a cycle.
Study NCT05667415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: on the first day of treatment, patients were given 80mg/m2 cisplatin intravenously, and 21 days was a course of treatment, lasting for 6 courses.
Study NCT06217614 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: (Manuka honey-green tea)
Description: Manuka honey is a natural honey, and green tea are herbs Dried green tea leaves (100 gm) will be soaked into 500 ml of methanol solution for two days. Green tea plus ginger mouthwash was prepared by adding 50% green tea extract and 50% ginger extract. After extraction, the extract was filtered and taker to the vacuum evaporator to remove the solvent.~The mouthwash was prepared by adding 3 gm of each extract, 0.12 gm sodium saccharin, and one liter distilled water, then every 20 ml of Manuka honey were added in 100 ml of (green tea and ginger solution). Finally, the mixture was stirred vigorously until all the particles were dissolved. Thereafter the obtained mixture was filtered. The mouthwash then filled in sterilized amber color bottles of 250 ml each.~According to similar studies performed in this field, the patients used a 20ml of (Manuka honey-green tea- ginger) mouthwash three times a day (preferably after their meals), kept it for one minute, and then poured it out
Study NCT04976270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3667
Description: GLPG3667 capsules
Study NCT04976270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules
Study NCT05999604 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ocrelizumab Injection [Ocrevus]
Description: Semestrial administration
Study NCT05999604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab Injection [Ocrevus]
Description: Annual administration
Study NCT05262348 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: adaptive DBS delivered through AlphaDBS IPG System
Description: The AlphaDBS IPG System delivers both conventional DBS and adaptive DBS. Adaptive DBS is a programming mode that provides stimulation in a closed-loop adaptive real-time fashion, using a biosignal recorded from the same macro-electrodes routinely implanted for DBS as an input variable.
Study NCT05262348 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional DBS delivered through AlphaDBS IPG System
Description: The AlphaDBS IPG System delivers both conventional DBS and adaptive DBS. Conventional DBS is programmed by DBS specialists.
Study NCT05444998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intuzumab, pyrrolidone, nab-paclitaxel
Description: Pyrrolidone 400 mg, qd; nab-paclitaxel 125 mg/m2, qw, D1/8/15; inituzumab 6 mg/kg (first dose 8 mg/kg) q3w, D1; 4 cycles in total (q3w as 1 cycle).~The patient's postoperative adjuvant therapy was 4 cycles of epirubicin + cyclophosphamide + physician's choice of anti-HER2 targeted therapy.~Multiple drug interruptions for adverse events were allowed throughout.
Study NCT05435820 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near-infrared Transcranial Laser Therapy
Description: The treatment consists in exposing bilaterally the frontal brain to Transcranial Laser Therapy, which may enhance ATP production in depressed subjects.
Study NCT05435820 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Near-infrared Transcranial Laser Therapy
Description: The treatment consists in exposing bilaterally the frontal brain to Transcranial Laser Therapy, which may enhance ATP production in depressed subjects.
Study NCT06226532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine spray
Description: Group SL: Spray 10% lidocaine for 4 puffs at the endotracheal tube cuff, also prepare for spray at the laryngeal inlet for 4 puffs (total approximately 1.5mg/kg)
Study NCT06226532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Lidocaine
Description: 2% lidocaine 1.5 mg/kg IV will be given 2 minutes after cisatracurium injection (3 minutes prior intubation).
Study NCT04992416 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate implant placement with ATBG and SMV
Description: immediate implant placement using ATBG as a graft material, with SMV
Study NCT04992416 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: immediate implant placement with ATBG
Description: immediate implant placement using ATBG as a graft material without SMV
Study NCT06450665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR Social Avoidance Intervention
Description: The intervention is based on cognitive-behavioral approach with a virtual coach acting as the therapist. It will be designed in tandem with input from Hong Kong users to ensure the scenario can resonate with them. By testing beliefs that inhibit confidence in a safe and controlled environment, participants will complete tasks with increasing difficulty in three VR scenarios and learn that they can cope in situations that they previously avoid.
Study NCT04825808 — intervention group
Intervention type: OTHER
Intervention: usual care
Description: according to recommendations
Study NCT04881968 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hopewell Hospitalist Video Game
Description: Hopewell Hospitalist is a customized theory-based adventure video game that uses narrative engagement to educate physician players on advance care planning to increase physicians' likelihood of engaging in and billing for ACP conversations.
Study NCT06300593 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement and comparison of leucocytosis and concentrations of C-reactive protein (CRP), interleukin-1 (IL-1), IL-6, IL-10, Tumor Necrosis Factor (TNF-alpha) in PCOS phenotypes A, B, C and D
Description: A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare the above parameters of peripheral blood in the four study arms
Study NCT06562413 — intervention group
Intervention type: DRUG
Intervention: MAbs
Description: Monthly or quarterly mAbs administration
Study NCT06300593 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of the correlation of serum concentrations of selected inflammatory markers (leucocytosis, CRP, IL-1, IL-6, IL-10, TNF-alpha) with metabolic and hormonal parameters
Description: A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to test the above correlations in the four study arms
Study NCT05652543 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01E
Description: Participants will be vaccinated with SCTV01E on Day 0, and safety and immunogenicity will be monitored for 180 days after vaccination.
Study NCT05652543 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (normal saline)
Description: Participants will be vaccinated with Placebo (normal saline) on Day 0, and safety and immunogenicity will be monitored for 180 days after vaccination.
Study NCT05100381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dry needling
Description: The patients will be placed in a prone position with a pillow under their belly to accommodate lumbar lordosis. Two lengths of sterile, disposable, 0.30 mm x 75 mm and 0.30 mm x 50 mm solid filament needle (Tony, China) will be used in this study. The length of the needle for each participant will be selected based on the size of the participant. The needles will be inserted into the lumbar multifidus muscle, 1.5 - 2 cm lateral to the spinous process of two or three painful segments, perpendicular to lamina (after piercing the skin, needles are directed inferomedially). The needles will be inserted to obtain local twitch response, and this process will continue until no more local twitch response occurs in each session. Then the needles will be left in place for 20 minutes.
Study NCT05100381 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sham (placebo) dry needling
Description: The sham dry needling method includes the insertion of the needles subcutaneously and no local twitch response will be obtained. The needles will be left in the place for 20 minutes.
Study NCT05599438 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT06140771 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 0.76% Sodium Monofluorophosphate Dentifrice
Description: Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
Study NCT06140771 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 1.15% Sodium Monofluorophosphate Dentifrice
Description: Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
Study NCT06326762 — intervention group
Intervention type: OTHER
Intervention: comparaison
Description: description indicate
Study NCT04901377 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Estradiol valerate/ Dienogest
Description: Combined hormonal contraceptive (combined oral contraceptives, COCs)
Study NCT06140771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.454% Stannous Fluoride Dentifrice
Description: Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
Study NCT05011487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: 80mg/qd oral for 60 days
Study NCT05011487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 2 cycles.
Study NCT04088422 — intervention group
Intervention type: PROCEDURE
Intervention: peripheral blood collection
Description: peripheral blood collection at treatment start, interm PET/CT, end of treatment PET/CT, one-year and two-year follow-up and or progression or relapse
Study NCT06387186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucine-Enriched Essential Amino Acid powder
Description: Leucine-Enriched Essential Amino Acid Powder will be orally/enterally administered by mixing in water or ketogenic formula.
Study NCT05011487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed (500 mg/m2) to be administered with cisplatin on Day 1 of every 3-week cycle for 2 cycles
Study NCT05957887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Assess the efficacy of Dapagliflozin on cardiac function and LV remodeling in acute ST elevation anterior myocardial infarction patients
Study NCT06058988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: All participants will receive T-DXd prior to indicated brain tumor resection/biopsy
Study NCT05963763 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Career Navigator Coaching
Description: The Career Navigator will support participants with a tailored approach to reach career and financial goals through one or more of the following services, in addition to referrals to other external services (community-based organizations) as needed for 6 months:~1. Career pathway navigation~2. Employee benefit maximization~3. Financial literacy and wealth building~4. Services funds for resources that mitigate specific barriers or needs.
Study NCT05409287 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate Implant Loading
Description: A single implant crown will be mounted on the implant immediately after implant placement
Study NCT05409287 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early Implant Loading
Description: A single implant crown will be mounted on the implant 4 weeks after implant placement.
Study NCT06370780 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: EPI LOVE
Description: Observational cohort only